INT54972

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 1994
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 3.31
Pain Relevance 0.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (EDNRA, EDNRB) signal transducer activity (EDNRA, EDNRB) cell proliferation (EDNRA)
signal transduction (EDNRA) aging (EDNRA)
Anatomy Link Frequency
superior 3
plasma 1
ependymal cells 1
EDNRA (Homo sapiens)
EDNRB (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 133 98.12 Very High Very High Very High
tetrodotoxin 1 76.80 Quite High
Inflammation 11 74.32 Quite High
fibrosis 6 73.64 Quite High
agonist 3 65.04 Quite High
Bioavailability 5 60.32 Quite High
cva 14 52.64 Quite High
ischemia 19 50.88 Quite High
Calcium channel 18 50.44 Quite High
Migraine 6 49.76 Quite Low
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 133 100.00 Very High Very High Very High
Pulmonary Hypertension 424 99.32 Very High Very High Very High
Stress 10 94.76 High High
Hypoxia 5 93.56 High High
Low Tension Glaucoma 17 76.48 Quite High
Glaucoma 101 76.28 Quite High
Cerebrovascular Disease 1 75.00 Quite High
INFLAMMATION 12 74.32 Quite High
Fibrosis 3 73.64 Quite High
Disease 97 60.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Endothelin causes contraction of human esophageal muscularis mucosae through interaction with both ETA and ETB receptors.
Endothelin Binding (interaction) of ETB
1) Confidence 0.52 Published 2004 Journal Regul. Pept. Section Title Doc Link 14749038 Disease Relevance 0 Pain Relevance 0.20
In the brain, at least two types of specific subreceptors have been cloned; ETA receptors, exclusively associated with blood vessels and ETB receptors also found on glial, epithelial, and ependymal cells.
ETA Binding (associated) of ETB in ependymal cells
2) Confidence 0.40 Published 1994 Journal Cephalalgia Section Abstract Doc Link 7954753 Disease Relevance 0.42 Pain Relevance 0.05
This suggests that low ET-1 doses have a greater affinity for ETB receptors to cause vasodilation, but increased levels of ET-1 leads to vasoconstriction by binding to ETA receptors.
ETA Binding (binding) of ETB associated with increased venous pressure under development
3) Confidence 0.12 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699797 Disease Relevance 0.79 Pain Relevance 0
At therapeutically relevant plasma concentrations in PAH, ambrisentan has higher receptor occupancy with ETA (> 90%), than ETB (<10%).
ETA Binding (occupancy) of ETB in plasma associated with pulmonary hypertension
4) Confidence 0.09 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.10 Pain Relevance 0.09
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
ETA Binding (affinity) of ETB in superior associated with antagonist
5) Confidence 0.09 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.55 Pain Relevance 0.14
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
ETA Binding (affinity) of ETB in superior associated with antagonist
6) Confidence 0.09 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.55 Pain Relevance 0.18
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
ETA Binding (affinity) of ETB in superior associated with antagonist
7) Confidence 0.09 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.55 Pain Relevance 0.18
An ETA:ETB binding ratio >2000:1 in a standard in vitro assay is considered selective for ETA (Sitbon et al 2004; Galie et al 2006).
ETA Binding (ratio) of ETB
8) Confidence 0.08 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.35 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox